Use of nebivolol in patients with idiopathic pulmonary hypertension: Results of the pilot study
AIM: Тo study the impact of 24-week therapy with nebivolol in a dose of 5 mg/day on the clinical and functional status of patients with idiopathic pulmonary hypertension (IPH), echocardiographic parameters, and blood levels of vasoactive mediators and nitric oxide (NO) metabolite. /MATERIAL AND METH...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2012-12-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/31150 |
| _version_ | 1818131886171488256 |
|---|---|
| author | T V Martyniuk I D Konosova I E Chazova |
| author_facet | T V Martyniuk I D Konosova I E Chazova |
| author_sort | T V Martyniuk |
| collection | DOAJ |
| description | AIM: Тo study the impact of 24-week therapy with nebivolol in a dose of 5 mg/day on the clinical and functional status of patients with idiopathic pulmonary hypertension (IPH), echocardiographic parameters, and blood levels of vasoactive mediators and nitric oxide (NO) metabolite. /MATERIAL AND METHODS: During continuous standard therapy comprising dihydropyridine calcium antagonists, warfarin, and diuretics, 12 patients with IPH and functional class (FC) II-III received nebivolol in a dose of 5 mg/day for 24 weeks. According to the data of right heart catheterization, all the patients had a positive acute pharmacological test with a vasodilator (NO). Six-minute walk test (6'WT), estimation of the Borg dyspnea index (BDI) and FC, transthoracic echocardiography (EchoCG), and measurements of the levels of NO metabolites, endothelin-1, (ET-1), thromboxane B2 (TxB2), and 6-keto-prostaglandin F1α (6-ketoPG F1α) were done at baseline and after 12 and 24 weeks of the therapy /RESULTS: Following 24-week nebivolol treatment, there was a statistically significant increase in 6'WT distance (from 473±47.6 to 516.7±58.4 m; р |
| first_indexed | 2024-12-11T08:28:03Z |
| format | Article |
| id | doaj.art-417e369a632a468d81d70e775293f9b9 |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-12-11T08:28:03Z |
| publishDate | 2012-12-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-417e369a632a468d81d70e775293f9b92022-12-22T01:14:30Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422012-12-018412495328166Use of nebivolol in patients with idiopathic pulmonary hypertension: Results of the pilot studyT V MartyniukI D KonosovaI E ChazovaAIM: Тo study the impact of 24-week therapy with nebivolol in a dose of 5 mg/day on the clinical and functional status of patients with idiopathic pulmonary hypertension (IPH), echocardiographic parameters, and blood levels of vasoactive mediators and nitric oxide (NO) metabolite. /MATERIAL AND METHODS: During continuous standard therapy comprising dihydropyridine calcium antagonists, warfarin, and diuretics, 12 patients with IPH and functional class (FC) II-III received nebivolol in a dose of 5 mg/day for 24 weeks. According to the data of right heart catheterization, all the patients had a positive acute pharmacological test with a vasodilator (NO). Six-minute walk test (6'WT), estimation of the Borg dyspnea index (BDI) and FC, transthoracic echocardiography (EchoCG), and measurements of the levels of NO metabolites, endothelin-1, (ET-1), thromboxane B2 (TxB2), and 6-keto-prostaglandin F1α (6-ketoPG F1α) were done at baseline and after 12 and 24 weeks of the therapy /RESULTS: Following 24-week nebivolol treatment, there was a statistically significant increase in 6'WT distance (from 473±47.6 to 516.7±58.4 m; рhttps://ter-arkhiv.ru/0040-3660/article/view/31150idiopathic pulmonary hypertensionright ventricleheart failureβ-adrenoblockersnebivolol |
| spellingShingle | T V Martyniuk I D Konosova I E Chazova Use of nebivolol in patients with idiopathic pulmonary hypertension: Results of the pilot study Терапевтический архив idiopathic pulmonary hypertension right ventricle heart failure β-adrenoblockers nebivolol |
| title | Use of nebivolol in patients with idiopathic pulmonary hypertension: Results of the pilot study |
| title_full | Use of nebivolol in patients with idiopathic pulmonary hypertension: Results of the pilot study |
| title_fullStr | Use of nebivolol in patients with idiopathic pulmonary hypertension: Results of the pilot study |
| title_full_unstemmed | Use of nebivolol in patients with idiopathic pulmonary hypertension: Results of the pilot study |
| title_short | Use of nebivolol in patients with idiopathic pulmonary hypertension: Results of the pilot study |
| title_sort | use of nebivolol in patients with idiopathic pulmonary hypertension results of the pilot study |
| topic | idiopathic pulmonary hypertension right ventricle heart failure β-adrenoblockers nebivolol |
| url | https://ter-arkhiv.ru/0040-3660/article/view/31150 |
| work_keys_str_mv | AT tvmartyniuk useofnebivololinpatientswithidiopathicpulmonaryhypertensionresultsofthepilotstudy AT idkonosova useofnebivololinpatientswithidiopathicpulmonaryhypertensionresultsofthepilotstudy AT iechazova useofnebivololinpatientswithidiopathicpulmonaryhypertensionresultsofthepilotstudy |